Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of First Patient Dosed in Phase III Clinical Trial of T-Bren (HER2 ADC) for First-Line Treatment of Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with HER2 Mutations

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis